Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

被引：0

作者：

Giuseppe Curigliano

Geoffrey I. Shapiro

Rebecca S. Kristeleit

Albiruni R. Abdul Razak

Stephen Leong

Maria Alsina

Antonio Giordano

Karen A. Gelmon

Erica Stringer-Reasor

Ulka N. Vaishampayan

Mark Middleton

Anthony J. Olszanski

Hope S. Rugo

Kenneth A. Kern

Nuzhat Pathan

Rachelle Perea

Kristen J. Pierce

Sarah C. Mutka

Zev A. Wainberg

机构：

[1] Istituto Europeo di Oncologia,Phase 1 Program

[2] IRCCS,undefined

[3] University of Milan,undefined

[4] Dana-Farber Cancer Institute,undefined

[5] University College London,undefined

[6] Cancer Institute,undefined

[7] Princess Margaret Cancer Centre,undefined

[8] University of Colorado Cancer Center,undefined

[9] Vall d’Hebron Institute of Oncology (VHIO),undefined

[10] Hollings Cancer Center,undefined

[11] Medical University of South Carolina,undefined

[12] BC Cancer,undefined

[13] University of Alabama at Birmingham O’Neal Comprehensive Cancer Center,undefined

[14] University of Michigan/Karmanos Cancer Institute,undefined

[15] Wayne State University,undefined

[16] University of Oxford,undefined

[17] Fox Chase Cancer Center,undefined

[18] University of California San Francisco Helen Diller Family Comprehensive Cancer Center,undefined

[19] Pfizer,undefined

[20] Pfizer,undefined

[21] Celcuity,undefined

[22] David Geffen School of Medicine at University of California,undefined

来源：

British Journal of Cancer | 2023年 / 128卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：400 / 400